Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Quinolone Stories

2014-04-01 08:22:33

ALBANY, New York, April 1, 2014 /PRNewswire/ -- MRRBIZ includes new market research report "Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides And Phenicols, And Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its large collection of research report. This report on antibacterial drugs market studies the current as well as future...

2014-03-26 16:25:09

DUBLIN, March 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/bn9wlv/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019" [http://www.researchandmarkets.com/research/bn9wlv/antibacterial ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) An antibacterial drug is referred to as an...

2014-03-24 08:29:42

FAIRFIELD, N.J., March 24, 2014 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today a licensing agreement with Ferrer, a privately-held Spanish pharmaceutical company, for the commercialization rights to Ozenoxacin 1% Cream in the United States. Ozenoxacin is a novel, bactericidal non-fluorinated quinolone in development as a topical treatment for impetigo. In 2013, Ferrer successfully completed the first Phase III Clinical Trial of Ozenoxacin in adult and pediatric...

2014-03-21 12:24:00

ALBANY, New York, March 21, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Antibacterial Drugs Market (By Class- Aminoglycosides, beta-Lactams, Tetracyclines, Sulfonamides, Quinolones/Fluoroquinolones, Macrolides and Phenicols, and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global antibacterial drugs market was valued at USD 43.55billion in 2012 and is expected to...

2014-03-14 23:04:14

Findings Shed Light On Cell Death Process, Drug's Toxicity Charlottesville, VA (PRWEB) March 14, 2014 A new discovery about how dying cells are removed from the body could have an unexpected and important benefit: allowing doctors to rehabilitate a powerful antibiotic now deemed too toxic for human use. Despite showing great initial promise, the antibiotic trovafloxacin was pulled from the market in the U.S. because of concerns about its toxicity. New research from the University of...

2014-02-20 23:23:30

Drug Allegedly Linked to Serious Muscle Problems and Nerve Damage Dallas, TX (PRWEB) February 20, 2014 The national law firm of Baron and Budd is now representing clients filing lawsuits against the maker of Cipro, an antibiotic that has been allegedly linked to nerve damage and peripheral neuropathy. This is a muscle condition that can lead to several problems, including difficulty walking, significant pain and arm and leg numbness. Cipro, the brand name for the drug ciprofloxacin, is...

2014-02-20 23:01:06

Antibiotic Allegedly Associated With Severe Nerve and Muscle Problems Dallas, TX (PRWEB) February 20, 2014 Baron and Budd, a national plaintiffs’ law firm, announced today that it is accepting lawsuits against the manufacturers of Levaquin, an antibiotic designed to treat bacterial illnesses and infections. The medication has been allegedly linked to a serious condition known as peripheral neuropathy, which can result in several types of sensory problems such as pain, diminished...

2014-01-15 04:21:44

TAIPEI, Jan. 15, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn(®)) in the Russian Federation, Turkey and other members of the Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria....

2013-12-23 04:20:43

TAIPEI, Dec. 23, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that the U.S. Food and Drug Administration (FDA) has granted nemonoxacin (Taigexyn(®)) Qualified Infectious Disease Product (QIDP) and Fast Track designations for community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSI). These two designations should enable TaiGen and/or its partners to benefit from certain incentives for the...

2013-11-27 15:08:04

In contrast to findings of a recent study, researchers in Denmark did not find an association between use of a class of antibiotics known as fluoroquinolones (such as ciprofloxacin) and an increased risk of retinal detachment, according to a study appearing in the November 27 issue of JAMA. Retinal detachment (a separation of the retina from its connection at the back of the eye) is an acute eye disorder that may lead to loss of vision despite prompt surgical intervention. A recent study...